Heart disease injury repairing method based on stem cells
The tumorigenic gene was removed and anti-tumor genes were inserted through CRISPR/Cas9 technology, and the stem cell differentiation was induced by combining growth factors and signaling molecules, which solved the problem of tumor formation risk in stem cell therapy and improved the safety and effectiveness of heart disease damage repair.
Patent Information
- Application Number
- CN202410945462.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-26
AI Technical Summary
Existing stem cells used in cardiac injury repair methods are difficult to control cell proliferation, which may lead to tumor formation and affect treatment safety.
Select the appropriate stem cell type, gene editing through CRISPR/Cas9 technology, remove potential tumorigenic genes and insert anti-tumor genes, ensure cell purity and differentiation status, and use specific growth factors and signaling molecules to induce stem cells to differentiate into cardiomyocytes. Combined with immunofluorescence detection and whole genome sequencing, quality inspection is carried out to ensure the safety and effectiveness of stem cells.
It significantly reduces the risk of tumor formation after stem cell transplantation, improves the safety and effectiveness of treatment, ensures the pluripotency and health of stem cells, and achieves the recovery of cardiac function.
Smart Images

Figure CN119015510A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cardiac damage repair, and more specifically, to a cardiac damage repair method based on stem cells. Background Art
[0002] Heart disease is one of the leading causes of death and disability worldwide. Heart attacks often lead to massive death of cardiomyocytes and permanent damage to heart function. Because the regenerative capacity of cardiomyocytes in adult mammals is extremely limited, traditional treatments, such as drugs, interventional therapy and surgery, are mainly aimed at alleviating symptoms and preventing further damage, but cannot reverse myocardial damage that has already occurred.
[0003] After myocardial infarction, scar tissue will form in the damaged area, leading to a decrease in the heart's contractile function. Repairing the damaged myocardium and restoring heart function are the key goals of heart disease treatment. Stem cells can differentiate into cardiomyocytes, vascular endothelial cells, etc., and are expected to repair damaged myocardium. Stem cells can also secrete various growth factors and cytokines to promote the survival, proliferation and angiogenesis of endogenous cardiomyocytes.
[0004] Among existing technologies, culturing stem cells for the treatment and repair of heart disease damage has great potential, but there are also major challenges. The proliferation of transplanted cells is difficult to control, so there is a certain possibility that tumors will develop after stem cells are implanted in the patient's heart, which will in turn create new problems that need to be solved.
[0005] Therefore, in response to the above technical problems, it is necessary to provide a method for repairing heart disease damage based on stem cells. Summary of the invention
[0006] The purpose of the present invention is to provide a method for repairing heart disease damage based on stem cells to solve the above-mentioned problems.
[0007] In order to achieve the above purpose, the technical solution provided by an embodiment of the present invention is as follows:
[0008] A method for repairing heart disease damage based on stem cells, comprising the following steps:
[0009] S1. Select appropriate stem cell types, including induced pluripotent stem cells and mesenchymal stem cells;
[0010] S2. Cultivation and expansion of stem cells: Cultivate and expand selected stem cells in vitro to obtain a sufficient number of cells for treatment, ensuring that the cells maintain their pluripotency and health during the culture process;
[0011] S3, differentiation of stem cells into cardiomyocytes. Specific growth factors and signal molecules are used to induce stem cells to differentiate into cardiomyocytes. During the differentiation process, cell phenotype and function are monitored to ensure that they have the characteristics of cardiomyocytes.
[0012] S4. Detect the purity of stem cells. Detect specific markers through immunofluorescence to ensure the purity and consistency of the stem cell population. Regularly check whether the stem cells remain in the expected differentiation state to prevent the residue of undifferentiated stem cells.
[0013] S5. Gene editing technology, using CRISPR / Cas9 technology to precisely modify stem cells, remove potential tumorigenic genes or insert anti-tumor genes, thereby reducing the risk of tumor formation;
[0014] S6, stem cell transplantation, which involves transplanting differentiated cardiomyocytes directly into the damaged heart area;
[0015] S7, cell survival and integration, using growth factors, cytokines or drugs to support cell survival, and promoting integration of cells into host tissues and functional recovery through physical stimulation;
[0016] S8. Functional recovery and monitoring: Regularly monitor the patient's heart function and evaluate the treatment effect through imaging examinations such as electrocardiogram, echocardiogram and MRI.
[0017] As a further improvement of the present invention, in step S2, the culture of stem cells needs to use optimized culture medium and additives to promote the directional differentiation of stem cells into cardiac cells, and appropriate growth factors and cytokines are added to induce the stem cells to develop along a safe and targeted differentiation path;
[0018] Choosing serum-free culture medium can reduce variability and make it easier to control the composition; additives can include B27 supplement, N2 supplement, L-glutamine, non-essential amino acids, and antibiotics such as penicillin-streptomycin mixture.
[0019] As a further improvement of the present invention, different combinations of growth factors and cytokines can induce stem cells to differentiate into specific types of cardiac cells. The following are some commonly used growth factors and cytokines:
[0020] S201, early differentiation stage:
[0021] ActivinA: Usually used to initiate mesoderm differentiation of embryonic stem cells or induced pluripotent stem cells;
[0022] BoneMorphogeneticProtein4: works with ActivinA to promote mesoderm formation and further development towards cardiac progenitor cells;
[0023] S202, mid-stage differentiation:
[0024] FibroblastGrowthFactor2: supports the proliferation and differentiation of mesoderm cells;
[0025] Wnt signaling pathway activator: activates the Wnt signaling pathway and promotes the differentiation of mesoderm into cardiac progenitor cells;
[0026] S203, late differentiation stage:
[0027] VEGF: promotes the maturation of cardiac cells and angiogenesis;
[0028] Insulin-likeGrowthFactor1: supports the growth and survival of cardiomyocytes;
[0029] BoneMorphogeneticProtein2: plays an important role in the differentiation of cardiac progenitor cells into cardiomyocytes.
[0030] As a further improvement of the present invention, the specific growth factors and signal molecules in step S3 include fibroblast growth factor and transforming growth factor β. The combination of fibroblast growth factor and transforming growth factor β is widely used in the culture and expansion of neural stem cells.
[0031] As a further improvement of the present invention, the immunofluorescence detection in step S4 refers to combining a specific antibody marker with a stem cell sample and then observing the expression of the marker using a fluorescence microscope. This method is very suitable for detecting the presence or absence of specific stem cell markers, thereby evaluating purity and differentiation status.
[0032] As a further improvement of the present invention, in step S4, the stem cells need to be tested by whole genome sequencing to ensure that no harmful gene mutations occur in the stem cells during in vitro amplification. Whole genome sequencing covers the entire genome and can detect all types of mutations.
[0033] As a further improvement of the present invention, the CRISPR / Cas9 technology in step S5 is a powerful gene editing tool that can make precise modifications in the cell genome. The application of this technology in stem cell therapy is particularly used to reduce the risk of tumor formation.
[0034] As a further improvement of the present invention, the application of the CRISPR / Cas9 technology includes:
[0035] S501. Eliminate potential tumorigenic genes. Through whole genome analysis, identify tumorigenic genes in stem cells that may lead to tumor formation. Use the CRISPR / Cas9 system to introduce double-strand breaks at specific sites of these tumorigenic genes, and inactivate or delete the genes through non-homologous end joining or homologous recombination repair pathways.
[0036] S502, insert anti-tumor genes. Select known anti-tumor genes that can inhibit cell proliferation or promote cell apoptosis, thereby reducing the risk of tumorigenesis. Design donor DNA with anti-tumor genes, introduce double-strand breaks at designated locations through CRISPR / Cas9, and precisely insert anti-tumor genes into the stem cell genome through homologous recombination;
[0037] S503. Enhance gene stability by using whole genome sequencing to detect potential mutations in stem cells, especially those associated with cancer, and use the CRISPR / Cas9 system to repair these mutations and restore the normal function of genes;
[0038] S504, control gene expression, use CRISPR interference or CRISPR activation system to inhibit or activate the expression of specific genes, respectively, edit gene regulatory regions to change the expression level of genes, reduce the expression of tumorigenic genes or increase the expression of anti-tumor genes;
[0039] S505, multiple gene editing, design multiple sgRNAs, and simultaneously edit multiple tumorigenic genes or related pathways to improve the safety of stem cells, combining multiple strategies of gene knockout, gene insertion, and gene expression regulation to provide a more comprehensive tumor prevention effect.
[0040] As a further improvement of the present invention, the known anti-tumor genes in step S502 include TP53, RB1, and PTEN;
[0041] The TP53 gene encodes the p53 protein, known as the "guardian of the genome". TP53 can be used for DNA damage repair, cell cycle arrest and induction of apoptosis;
[0042] The RB1 gene encodes the retinoblastoma protein, which inhibits cell proliferation by regulating cell cycle progression;
[0043] The PTEN gene encodes a phosphatase that negatively regulates the PI3K / AKT signaling pathway, which is involved in cell growth and survival.
[0044] As a further improvement of the present invention, the stem cell transplantation method in step S6 includes:
[0045] S601. Direct injection, either intravenously, intracoronarily or intramyocardially;
[0046] S602, tissue engineering scaffolds, cells are implanted into scaffold materials, and then the scaffolds are transplanted into the damaged area of the heart, which helps the cells to colonize and survive.
[0047] Compared with the prior art, the advantages of the present invention are:
[0048] This program can achieve the purpose of repairing heart disease damage by selecting induced pluripotent stem cells and mesenchymal stem cells for culture and expansion. After the stem cells are differentiated, the stem cells are quality inspected by immunofluorescence detection technology to ensure that the stem cells remain in the expected differentiation state. The stem cells are also tested by whole genome sequencing to ensure that no harmful gene mutations occur during the in vitro expansion of the stem cells. After the purity of the stem cells reaches the standard, the CRISPR / Cas9 technology is used to accurately modify the stem cells to remove potential tumorigenic genes and insert anti-tumor genes, thereby reducing the risk of tumor formation. The application of CRISPR / Cas9 technology in stem cell therapy provides a powerful tool for reducing the risk of tumor formation. By accurately modifying the stem cell genome, removing tumorigenic genes, inserting anti-tumor genes, repairing mutations and regulating gene expression, the safety of stem cell therapy can be significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 The present invention is a flow chart of the method. DETAILED DESCRIPTION
[0050] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention; it is obvious that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments, and all other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making creative work are within the scope of protection of the present invention.
[0051] Embodiment 1:
[0052] See also Figure 1 , a method for repairing heart disease damage based on stem cells, comprising the following steps:
[0053] S1. Select appropriate stem cell types, including induced pluripotent stem cells and mesenchymal stem cells;
[0054] S2. Cultivation and expansion of stem cells: Cultivate and expand selected stem cells in vitro to obtain a sufficient number of cells for treatment, ensuring that the cells maintain their pluripotency and health during the culture process;
[0055] S3, differentiation of stem cells into cardiomyocytes. Specific growth factors and signal molecules are used to induce stem cells to differentiate into cardiomyocytes. During the differentiation process, cell phenotype and function are monitored to ensure that they have the characteristics of cardiomyocytes.
[0056] S4. Detect the purity of stem cells. Detect specific markers through immunofluorescence to ensure the purity and consistency of the stem cell population. Regularly check whether the stem cells remain in the expected differentiation state to prevent the residue of undifferentiated stem cells.
[0057] S5. Gene editing technology, using CRISPR / Cas9 technology to precisely modify stem cells, remove potential tumorigenic genes and insert anti-tumor genes, thereby reducing the risk of tumor formation;
[0058] S6, stem cell transplantation, which involves transplanting differentiated cardiomyocytes directly into the damaged heart area;
[0059] S7, cell survival and integration, using growth factors, cytokines or drugs to support cell survival, and promoting integration of cells into host tissues and functional recovery through physical stimulation;
[0060] S8. Functional recovery and monitoring: Regularly monitor the patient's heart function and evaluate the treatment effect through imaging examinations such as electrocardiogram, echocardiogram and MRI.
[0061] In step S2, the culture of stem cells requires the use of optimized culture medium and additives to promote the directed differentiation of stem cells into cardiac cells, and the addition of appropriate growth factors and cytokines to induce the stem cells to develop along a safe and targeted differentiation path;
[0062] Choosing serum-free culture medium can reduce variability and make it easier to control the composition; additives can include B27 supplement, N2 supplement, L-glutamine, non-essential amino acids, and antibiotics such as penicillin-streptomycin mixture.
[0063] Specifically, the choice of serum-free culture medium reduces the variability and potential risk of pathogen contamination from serum, makes it easier to control culture conditions, and the addition of supplements can promote cell differentiation and proliferation, support cell metabolism, and prevent bacterial contamination.
[0064] Different combinations of growth factors and cytokines can induce stem cells to differentiate into specific types of heart cells. The following are some commonly used growth factors and cytokines:
[0065] S201, early differentiation stage:
[0066] ActivinA: Usually used to initiate mesoderm differentiation of embryonic stem cells or induced pluripotent stem cells;
[0067] BoneMorphogeneticProtein4: works with ActivinA to promote mesoderm formation and further development towards cardiac progenitor cells;
[0068] S202, mid-stage differentiation:
[0069] FibroblastGrowthFactor2: supports the proliferation and differentiation of mesoderm cells;
[0070] Wnt signaling pathway activator: activates the Wnt signaling pathway and promotes the differentiation of mesoderm into cardiac progenitor cells;
[0071] S203, late differentiation stage:
[0072] VEGF: promotes the maturation of cardiac cells and angiogenesis;
[0073] Insulin-likeGrowthFactor1: supports the growth and survival of cardiomyocytes;
[0074] BoneMorphogeneticProtein2: plays an important role in the differentiation of cardiac progenitor cells into cardiomyocytes.
[0075] Specifically, by carefully designing and optimizing the combined use of these growth factors and cytokines, researchers can more effectively control the differentiation process of stem cells into heart cells, providing more possibilities for cardiac regenerative medicine research.
[0076] The specific growth factors and signal molecules in step S3 include fibroblast growth factor and transforming growth factor β. The combination of fibroblast growth factor and transforming growth factor β is widely used in the culture and expansion of neural stem cells.
[0077] Specifically, by using fibroblast growth factor and transforming growth factor β in combination, the proliferation and differentiation process of neural stem cells can be more accurately controlled. The combined use of these factors can more effectively amplify neural stem cells and induce their differentiation, thereby improving culture efficiency and yield.
[0078] Immunofluorescence detection in step S4 refers to combining a specific antibody marker with a stem cell sample and then observing the expression of the marker using a fluorescence microscope. This method is very suitable for detecting the presence or absence of specific stem cell markers to evaluate purity and differentiation status;
[0079] In step S4, the stem cells also need to be tested by whole genome sequencing to ensure that no harmful gene mutations occur in the stem cells during in vitro expansion. Whole genome sequencing covers the entire genome and can detect all types of mutations.
[0080] Specifically, in stem cell research, immunofluorescence detection and whole genome sequencing complement each other. Immunofluorescence detection can quickly evaluate the expression of specific markers on the cell surface and inside, thereby confirming the differentiation state and purity of the cells. Whole genome sequencing can comprehensively monitor the genomic stability of stem cells during in vitro expansion to ensure that there is no accumulation of harmful mutations. The combination of these two methods can provide comprehensive quality control for stem cell research and ensure the reliability and repeatability of experimental results.
[0081] The CRISPR / Cas9 technology in step S5 is a powerful gene editing tool that can make precise modifications in the cell genome. This technology is used in stem cell therapy, especially to reduce the risk of tumor formation;
[0082] Applications of CRISPR / Cas9 technology include:
[0083] S501. Eliminate potential tumorigenic genes. Through whole genome analysis, identify tumorigenic genes in stem cells that may lead to tumor formation. Use the CRISPR / Cas9 system to introduce double-strand breaks at specific sites of these tumorigenic genes, and inactivate or delete the genes through non-homologous end joining or homologous recombination repair pathways.
[0084] S502, insert anti-tumor genes. Select known anti-tumor genes that can inhibit cell proliferation or promote cell apoptosis, thereby reducing the risk of tumorigenesis. Design donor DNA with anti-tumor genes, introduce double-strand breaks at designated locations through CRISPR / Cas9, and precisely insert anti-tumor genes into the stem cell genome through homologous recombination;
[0085] S503. Enhance gene stability by using whole genome sequencing to detect potential mutations in stem cells, especially those associated with cancer, and use the CRISPR / Cas9 system to repair these mutations and restore the normal function of genes;
[0086] S504, control gene expression, use CRISPR interference or CRISPR activation system to inhibit or activate the expression of specific genes, respectively, edit gene regulatory regions to change the expression level of genes, reduce the expression of tumorigenic genes or increase the expression of anti-tumor genes;
[0087] S505, multiple gene editing, design multiple sgRNAs, and simultaneously edit multiple tumorigenic genes or related pathways to improve the safety of stem cells, combining multiple strategies of gene knockout, gene insertion, and gene expression regulation to provide a more comprehensive tumor prevention effect.
[0088] The known anti-tumor genes in step S502 include TP53, RB1, and PTEN;
[0089] The TP53 gene encodes the p53 protein, known as the "guardian of the genome". TP53 can be used for DNA damage repair, cell cycle arrest and induction of apoptosis;
[0090] The RB1 gene encodes the retinoblastoma protein, which inhibits cell proliferation by regulating cell cycle progression;
[0091] The PTEN gene encodes a phosphatase that negatively regulates the PI3K / AKT signaling pathway, which is involved in cell growth and survival.
[0092] Specifically, precise gene editing through CRISPR / Cas9 technology can remove potential tumorigenic genes in stem cells, insert anti-tumor genes, enhance gene stability, control gene expression, and perform multiple gene editing, thereby providing a more comprehensive effect for tumor prevention.
[0093] The stem cell transplantation method in step S6 includes:
[0094] S601. Direct injection, either intravenously, intracoronarily or intramyocardially;
[0095] S602, tissue engineering scaffolds, cells are implanted into scaffold materials, and then the scaffolds are transplanted into the damaged area of the heart, which helps the cells to colonize and survive.
[0096] Specifically, direct injection is relatively simple to operate and can quickly deliver stem cells to the target area. Tissue engineering scaffolds provide mechanical support, which helps cells to colonize and survive for a long time in the target area. They can simulate the natural tissue environment and promote cell function.
[0097] It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and scope of the equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.
[0098] In addition, it should be understood that although the present specification is described according to embodiments, not every embodiment contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation methods that those skilled in the art can understand.
Claims
1. A method for repairing heart disease damage based on stem cells, characterized in that: The following steps are involved: S1. Select appropriate stem cell types, including induced pluripotent stem cells and mesenchymal stem cells; S2. Cultivation and expansion of stem cells: Cultivate and expand selected stem cells in vitro to obtain a sufficient number of cells for treatment, ensuring that the cells maintain their pluripotency and health during the culture process; S3, differentiation of stem cells into cardiomyocytes. Specific growth factors and signal molecules are used to induce stem cells to differentiate into cardiomyocytes. During the differentiation process, cell phenotype and function are monitored to ensure that they have the characteristics of cardiomyocytes. S4. Detect the purity of stem cells. Detect specific markers through immunofluorescence to ensure the purity and consistency of the stem cell population. Regularly check whether the stem cells remain in the expected differentiation state to prevent the residue of undifferentiated stem cells. S5. Gene editing technology, using CRISPR / Cas9 technology to precisely modify stem cells, remove potential tumorigenic genes and insert anti-tumor genes, thereby reducing the risk of tumor formation; S6, stem cell transplantation, which involves transplanting differentiated cardiomyocytes directly into the damaged heart area; S7, cell survival and integration, using growth factors, cytokines or drugs to support cell survival, and promoting integration of cells into host tissues and functional recovery through physical stimulation; S8. Functional recovery and monitoring: Regularly monitor the patient's heart function and evaluate the treatment effect through imaging examinations such as electrocardiogram, echocardiogram and MRI.
2. A method for repairing heart disease damage based on stem cells according to claim 1, characterized in that: In step S2, the culture of stem cells requires the use of optimized culture medium and additives to promote the directional differentiation of stem cells into cardiac cells, and the addition of appropriate growth factors and cytokines to induce the stem cells to develop along a safe and targeted differentiation path; Choosing serum-free culture medium can reduce variability and make it easier to control the composition; additives can include B27 supplement, N2 supplement, L-glutamine, non-essential amino acids, and antibiotics such as penicillin-streptomycin mixture.
3. A method for repairing heart disease damage based on stem cells according to claim 2, characterized in that: Different combinations of growth factors and cytokines can induce stem cells to differentiate into specific types of heart cells. The following are some commonly used growth factors and cytokines: S201, early differentiation stage: ActivinA: Usually used to initiate mesoderm differentiation of embryonic stem cells or induced pluripotent stem cells; BoneMorphogeneticProtein4: works with ActivinA to promote mesoderm formation and further development towards cardiac progenitor cells; S202, mid-stage differentiation: FibroblastGrowthFactor2: supports the proliferation and differentiation of mesoderm cells; Wnt signaling pathway activator: activates the Wnt signaling pathway and promotes the differentiation of mesoderm into cardiac progenitor cells; S203, late differentiation stage: VEGF: promotes the maturation of cardiac cells and angiogenesis; Insulin-likeGrowthFactor1: supports the growth and survival of cardiomyocytes; BoneMorphogeneticProtein2: plays an important role in the differentiation of cardiac progenitor cells into cardiomyocytes.
4. A method for repairing heart disease damage based on stem cells according to claim 1, characterized in that: The specific growth factors and signal molecules in step S3 include fibroblast growth factor and transforming growth factor β. The combination of fibroblast growth factor and transforming growth factor β is widely used in the culture and expansion of neural stem cells.
5. The method for repairing heart disease damage based on stem cells according to claim 1, characterized in that: The immunofluorescence detection in step S4 refers to combining a specific antibody marker with a stem cell sample and then observing the expression of the marker using a fluorescence microscope. This method is very suitable for detecting the presence or absence of specific stem cell markers, thereby evaluating purity and differentiation status.
6. A method for repairing heart disease damage based on stem cells according to claim 5, characterized in that: In step S4, the stem cells also need to be tested by whole genome sequencing to ensure that no harmful gene mutations occur in the stem cells during in vitro expansion. Whole genome sequencing covers the entire genome and can detect all types of mutations.
7. The method for repairing heart disease damage based on stem cells according to claim 1, characterized in that: The CRISPR / Cas9 technology in step S5 is a powerful gene editing tool that can make precise modifications in the cell genome. This technology is used in stem cell therapy, especially to reduce the risk of tumor formation.
8. A method for repairing heart disease damage based on stem cells according to claim 7, characterized in that: Applications of the CRISPR / Cas9 technology include: S501. Eliminate potential tumorigenic genes. Through whole genome analysis, identify tumorigenic genes in stem cells that may lead to tumor formation. Use the CRISPR / Cas9 system to introduce double-strand breaks at specific sites of these tumorigenic genes, and inactivate or delete the genes through non-homologous end joining or homologous recombination repair pathways. S502, insert anti-tumor genes. Select known anti-tumor genes that can inhibit cell proliferation or promote cell apoptosis, thereby reducing the risk of tumorigenesis. Design donor DNA with anti-tumor genes, introduce double-strand breaks at designated locations through CRISPR / Cas9, and precisely insert anti-tumor genes into the stem cell genome through homologous recombination; S503. Enhance gene stability by using whole genome sequencing to detect potential mutations in stem cells, especially those associated with cancer, and use the CRISPR / Cas9 system to repair these mutations and restore the normal function of genes; S504, control gene expression, use CRISPR interference or CRISPR activation system to inhibit or activate the expression of specific genes, respectively, edit gene regulatory regions to change the expression level of genes, reduce the expression of tumorigenic genes or increase the expression of anti-tumor genes; S505, multiple gene editing, design multiple sgRNAs, and simultaneously edit multiple tumorigenic genes or related pathways to improve the safety of stem cells, combining multiple strategies of gene knockout, gene insertion, and gene expression regulation to provide a more comprehensive tumor prevention effect.
9. A method for repairing heart disease damage based on stem cells according to claim 8, characterized in that: The known anti-tumor genes in step S502 include TP53, RB1, and PTEN; The TP53 gene encodes the p53 protein, known as the "guardian of the genome". TP53 can be used for DNA damage repair, cell cycle arrest and induction of apoptosis; The RB1 gene encodes the retinoblastoma protein, which inhibits cell proliferation by regulating cell cycle progression; The PTEN gene encodes a phosphatase that negatively regulates the PI3K / AKT signaling pathway, which is involved in cell growth and survival.
10. The method for repairing heart disease damage based on stem cells according to claim 1, characterized in that: The stem cell transplantation method in step S6 includes: S601. Direct injection, either intravenously, intracoronarily or intramyocardially; S602, tissue engineering scaffolds, cells are implanted into scaffold materials, and then the scaffolds are transplanted into the damaged area of the heart, which helps the cells to colonize and survive.
